Skip to main content
. Author manuscript; available in PMC: 2012 Aug 28.
Published in final edited form as: Antivir Ther. 2010;15(1):41–49. doi: 10.3851/IMP1489

Table 2. Immunological and virological characteristics and HAART type, by treatment sub-group.

HAART type at
conception		 First antenatal
CD4 count
Median (IQR)
cells/mm3 		First antenatal
HIV RNA
Median (IQR)
log10 copies/ml 		Timing of first
antenatal
measurement
Median (IQR)
Gest weeks		 Gestational age
at interruption
or switch
Median (IQR)		 N (%) with
undetectable HIV
RNA levels in 4
weeks up to
delivery
PI-based
N (%)		 NNRTI-
based N (%)
No change to regimen
n=72		 49 (68) 23 (32) 421
(304-560)		 2.77
(2.44-3.65)		 12 (8-22) N/A 24/60 (40)
Interruption of HAART
n=31		 14 (45) 17 (55) 360
(270-412)		 4.08
(3.37-4.45)		 12 (9-16) 7 weeks (5-8) 10/24 (42)
Switch to new regimen
n=24		 15 (63) 9 (38) 306
(208-447)		 3.12
(2.91-3.48)		 10 (6-16) 21 weeks (15-24) 5/19 (26)